This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Eva Carina Sum: Innovator in Bispecific Antigen Binding Molecules
Introduction
Eva Carina Sum is a prominent inventor based in Schlieren, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific antigen binding molecules. Her innovative work has the potential to impact therapeutic approaches in various medical conditions.
Latest Patents
Eva Carina Sum holds a patent for bispecific antigen binding molecules capable of specific binding to CD40 and to Fibroblast Activation Protein (FAP). This invention relates to novel bispecific antigen binding molecules, which comprise at least one antigen binding domain capable of specific binding to CD40, and at least one antigen binding domain capable of specific binding to a target cell antigen. The methods of producing these molecules and their applications are also covered in her patent.
Career Highlights
Throughout her career, Eva has worked with notable companies, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in the field of biotechnology.
Collaborations
Eva has collaborated with esteemed colleagues such as Peter Bruenker and Alexander Bujotzek. These partnerships have fostered an environment of innovation and have led to advancements in her research endeavors.
Conclusion
Eva Carina Sum is a trailblazer in the field of bispecific antigen binding molecules, with a patent that showcases her innovative spirit. Her work continues to influence the biotechnology landscape, paving the way for future advancements in medical therapies.